Initiate initial study during PCI in Elective and Non-Urgent NSTEMI for Temanogrel
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initial study during PCI in Elective and Non-Urgent NSTEMI – Q2 2021”
What we found
Evidence strength A What the grades mean
The company initiated a Phase 2 trial evaluating intravenous temanogrel for cMVO in patients undergoing PCI in June 2021, meeting the Q2 2021 deadline.
-
A Arena Pharmaceuticals Inc. 10-Q filed 2021-08-05
“In June 2021, the first participant had been randomized in a Phase 2 trial evaluating intravenous temanogrel for the potential treatment of cMVO in patients undergoing percutaneous coronary intervention (“PCI”).” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Temanogrel initial study
- In the company’s control
- High
- Specificity
- High
- Conditional
- Yes: Subject to COVID-19 Impact
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Arena Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C080709-021816 · Corrections policy